DXCM

DexComC

Nasdaq / Health Care Equipment & Services

Quote time unavailable

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+1

B+

Bull case

25%

Probability

Target price

$100.00

Analysis reference price unavailable

Analysis 2026-10-23 · RankAlpha Sentiment Codex

Most likely

Base case

50%

Probability

Target price

$86.00

Analysis reference price unavailable

Analysis 2026-10-23 · RankAlpha Sentiment Codex

B-

Bear case

25%

Probability

Target price

$62.00

Analysis reference price unavailable

Analysis 2026-10-23 · RankAlpha Sentiment Codex

The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented

AI sentiment snapshot

Latest data as of 2026-10-23

AI commentary

The October 22 anchor is $78.32, but it predates the company-confirmed October 29 Q3 release; an earnings-driven price reaction cannot be calculated. No post-print analyst target or estimate revisions exist yet. The scheduled-date mismatch outweighs the positive deterministic prior for this follow-up; sentiment figures other than headline buzz are unavailable, and zeros above denote unavailable data rather than measured neutral readings.

RankAlpha Sentiment Codex - 2026-10-23

Open post-earnings memo

Evidence flagged

peer set is too generic or lacks enough direct operating comparators

Impact

tentative

Confidence

AI events

2026-10-29eventThird-quarter results are due October 29—not October 22Medium impact

Dexcom says it will release Q3 results after market close on October 29. The scheduled T+1 trigger is premature; no Q3 earnings surprise or post-print reaction can yet be assessed. The report will test progress against July's $5.18–$5.25 billion full-year revenue guidance and 23.5%–24% non-GAAP operating-margin guidance. [#IR-2026-10-07] [#SEC-8K-2026-07-30] [#10-Q-2026-07-30] https://investors.dexcom.com/news/news-details/2026/Dexcom-Schedules-Third-Quarter-2026-Earnings-Release-and-Conference-Call-for-October-29-2026-at-430-p-m--Eastern-Time/default.aspx

2027-01-21catalystStelo app relaunch executionMedium impact

Dexcom said it initiated a redesigned Stelo app launch in Q2, adding AI-driven insights and food logging. Evidence of customer uptake or incremental revenue is not yet supplied; upcoming disclosures could clarify traction. [#SEC-8K-2026-07-30]

2027-10-23catalystCONNECT results may support broader CGM adoptionHigh impact

Dexcom reported positive CONNECT trial results for people with type 2 diabetes not using insulin. Clinical evidence is established in the July release, but the pace of coverage expansion and commercial conversion remains unproven in this packet. [#SEC-8K-2026-07-30]

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-10-23 • Updated nightlySource: Internal modelMethodology